Stereotactic Body Radiotherapy
Cross-source consensus on Stereotactic Body Radiotherapy from 1 sources and 6 claims.
1 sources · 6 claims
How it works
Dosage & preparation
Preparation
Evidence quality
Highlighted claims
- The SBRT arm prescribes 36.25 Gy in 5 fractions over 1-2 weeks on a linear accelerator. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer
- Ultra-hypofractionated EBRT, also called SBRT, delivers more than 5 Gy per fraction and can complete treatment in as few as five sessions. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer
- For low-risk patients, the SBRT clinical target volume is the prostate only. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer
- For intermediate-risk patients, the SBRT clinical target volume includes the prostate and proximal 1 cm of seminal vesicles. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer
- The rationale for SBRT in prostate cancer is that prostate cancer has a low alpha/beta ratio compared with surrounding healthy tissue. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer
- The PACE-B trial showed level I evidence that five-fraction SBRT was non-inferior to moderately hypofractionated 20-fraction radiotherapy with comparable toxicity. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer